Substitute for form 1449A/B/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

4

Complete if Known					
Application Number	09/914,708				
Filing Date	August 31, 2001				
First Named Inventor	BOYD, Michael R.				
Group Art Unit	1617				
Examiner Name	Shengjun Wang				
Attorney Docket Number	213045				
Client Reference No.	E-244-1997/3-US-06				

U.S. PATENT DOCUMENTS						
		U.S. Patent Doc	ument			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS								
Foreign Patent Document			oreign Patent Documer	nt			Trans	lation
Examiner Initials	Doc.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
/SW/	AA	WO	99/05136	A1	The United States of America	Feb. 04, 1999		
/SW/	AB	wo	00/51589	A2	The United States of America	Sep. 08, 2000		
/SW/	AC	WO	00/51589	A3	The United States of America	Jul. 12, 2001		

Examiner Do			OTHER - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Trans	slation	
Examiner Initials /SW/		Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No**	
/SW/		AD	Akifusa et al., Exp. Cell Res., 238, 82-89 (1998)			
AE			Aldridge et al., J. Chem. Soc., 1623-1627 (1971)			
		AF	Altan et al., J. Exp. Med., 187, 1583-1598 (1998)			
		AG	Arabshahi et al., Tetrahedron Lett., 29, 10, 1099-1102 (1988)			
AH			Benderra et al., Int. J. Onco., 12, 711-715 (1998)			
Al			Benslimane et al., J. Natural Prod., 51, 3, 582-583 (1988)			
AJ			Blair et al., Science, 245, 855-857 (1987)			
		AK	Bowman et al., Proc. Natl. Acad. Sci. USA, 85, 7972-7976 (1988)		l	
		AL	Boyd and Paull, Drug Dev. Res., 34, 91-109 (1995)			
		AM	Boyd, Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (Teicher, B.A., ed.) Totowa, NJ: Humana Press, Inc., pp. 23-42 (1997)			
		AN	Boyd, Current Therapy in Oncology (Niederhuber, ed.), Philadelphia: B.C. Decker, Inc., pp. 11-22 (1993)			
		AO	Boyd, Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development (Valeriote, F.A. et al., eds.) Amsterdam: Kluwer Academic Publishers, pp. 11-34 (1992)			
		AP	Boyd: Cancer: Principles and Practice of Oncology Updates (DeVita, V.T., Jr., et al., eds), Philadelphia: Lippincott, 3, 11-22 (1989)			
		AQ	Broady et al., J. Chem. Soc. Chem. Commun. 708-711 (1991)			
		AR	Carmeli et al., J. Nat. Prod., 53, 6, 1533-1542 (1990)			
AS			Caroll et al., Aust. J. Chem., 46, 825-832 (1993)			
		AT	Chan et al., Anal. Biochem., 157, 375-380 (1986)			
		AU	Charan et al., Tetrahedron, 52, 27, 9111-9120 (1996)			
		AV	Choukchou-Braham et al., Tetrahedron Lett., 35, 23, 3949-3952 (1994)			
1	7	AW	Collins, Cancer Chemotherapy: Principles and Practice, 2, J.B. Lippincott, 16-31 (1990)			
V	7	AX	Copp et al., Tetrahedron Lett., 30, 28, 3703-3706 (1989)			
/SV	N/	AY	Dale et al., J. Am. Chem. Soc., 95, 512-519 (1973)		l	

Examiner Signature	/Shengjun Wang/	Date Considered	04/24/2008

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1,98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1,36(a)(3).

Sheet

## Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

		Complete if Known
	Application Number	09/914,708
	Filing Date	August 31, 2001
	First Named Inventor	BOYD, Michael R.
	Group Art Unit	1617
	Examiner Name	Shengjun Wang
	Attorney Docket Number	213045
-	Client Reference No.	F-244-1997/3-HS-06

		OTHER - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,	Tran	slation
Examiner	Doc.	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city	Yes	No*+
Initials	No.	and/or country where published.	169	NO.
/SW/	AZ	D'Auria et al., Tetrahedron, 49, 38, 8657-8664 (1993)		
1	BA	David et al., Exp. Opin. Invest. Drugs, 4, 725-740 (1995)		
	ВВ	Dekker et al., J. Antibiotics, 51, 14-20 (1998)		
	ВС	Doi et al., Tetrahedron, 50, 29, 8651-8656 (1994)		
	BD	Dröse et al., Biochemistry, 32, 3902-3906 (1993)		
$\neg$	BE	Dröse et al., J. Exp. Biol. 200, 1-8 (1997)		
_	BF	Durgnat et al., Helvetica Chim. Acta, 76, 222-240 (1993)		
	BG	Erickson et al., J. Org. Chem., 62, 23, 8188-8192 (1997)		
BH BI BJ BK BL BM BN BO		Farina et al., Therapeutic Focus, 4, 4, 163-172 (1999)		
		Faulkner et al., Marine Nat. Prod., 9, 497-539 (1992)		
		Fenical et al., Marine Tech. Soc., 388-394 (1974)		
		Finbow et al., Biochem. J., 324, 697-712 (1997)		
		Forgac, Physiological Rev., 69, 765-796 (1989)		П
		Fu et al., J. Am. Chem. Soc., 116, 12125-12126 (1994)		
		Furstner et al., Tetrahedron, 55, 8215-8230 (1999)		
		Fusetani et al., Tetrahedron Lett., 30, 21, 2809-2812 (1989)		
-	BP	Gagliardi et al., J. Med. Chem, 41, 1883-1893 (1998)		
	BQ	Gagliardi et al., J. Med. Chem., 41, 1568-1573 (1998)		
	BR	Galinis et al., J. Org. Chem., 62, 8968-8969 (1997)		
	BS	Gerard et al., J. Exp. Biol., 201, 21-31 (1998)		
	BT	Ghosh et al., <i>Tetrahedron Lett.</i> , 39, 8803-8806 (1998)		
-	BU	Gordon et al., J. Org. Chem., 49, 97-100 (1984)	-	-
	BV	Grever et al., Cancer Principles and Practice of Oncology, 5 <sup>th</sup> Ed. (Devita et al., eds.)	<u> </u>	<b>-</b>
	ВV	Philadelphia: Lippincott-Raven, pp. 385-394 (1977)	l	1
-	BW	Guella et al., Helvetica Chim Acta, 70, 621-626 (1987)		
-	BX	Hall et al., Bone and Mineral, 27, 159-166 (1994)		
-		Hall et al., Inflamm. Res., 45, 1-9 (1996)	<b>†</b>	1
BY BZ		Howard et al., Tetrahedron Lett., 46, 4449-4452 (1979)		$\vdash$
		Ishii et al., J. Antibiot., 48, 12-20 (1995)	+	_
_	CA	Jaspars et al., J. Org. Chem., 59, 3253-3255 (1994)		-
	CB	Jensen et al., J. Org. Chem., 37, 10, 1639-1647 (1972)	_	+-
	CC	Johnston et al., J. Org. Chem., 37, 10, 1635-1647 (1972)	+	+-
	CD	Johnston et al., J. Wed. Crieff., 13, 3, 941-944 (1970)	+-	+-
	CE	Kaneko et al., Tetrahedron Lett., 35, 4107-4110 (1994)	+-	+
	CF	Keeling et al., Ann. New York Acad. Sci, 834, 600-608 (1997)	+	+
	CG	Keman et al., J. Org. Chem., 53. 5014-5020 (1988)	+	+-
	СН	Keman et al., Tetrahedron Lett., 28, 25, 2809-2812 (1987)	+	+
$\Delta V$	CI	Kim et al., J. Natural Prod., 56, 10, 1813-1816 (1993)	-	+-
- ▼	CJ	Kim et al., J. Org. Chem. 64, 153-155 (1999)	┼	+-
/SW/	CK	Kinoshita et al., FEBS Lett., 337, 221-225 (1994)		_

Examiner Signature	/Shengjun Wang/	Date Considered	04/24/2008

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

A Source statement or received is being sourmined in red of a constant. 2 of CF1 (1969(5)).

An English-language equivalent/peach, or an English-language abstract or an English-language revision of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 2 of CF1 (1968(6)).

Sheet

outsitute for form 1445/05h 10	
INFORMATION	DISCLOSURE
STATEMENT B	Y APPLICANT

3

(Use as many sheets as necessary)

of

4

_		Complete if Known		
	Application Number	09/914,708		
	Filing Date	August 31, 2001		
	First Named Inventor	BOYD, Michael R.		
	Group Art Unit	1617		
	Examiner Name	Shengjun Wang		
	Attorney Docket Number	213045		
	Client Reference No.	E-244-1997/3-US-06		

		OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city		_		
Initials	No.	and/or country where published.	Yes	No**		
/SW/	CL	Kinoshita et al., FEBS Lett., 398, 61-66 (1996)		Franslation		
1	CM	Kobayashi et al., J. Natural Prod., 56, 5, 787-791 (1993)				
1	CN	Kobayashi et al., J. Org. Chem., 59, 255-257 (1994)				
	CO	Kobayashi et al., Tetrahedron, 51, 13, 3727-3736 (1995)				
	CP	Kunze et al., J. Antibiotics, 51, 1075-1080 (1998)				
$\top$	CQ	Leclercq et al., Tetrahedron Lett., 50,84 65-8488 (1994)				
1	CR	Manabe et al., J. Cell Physiol., 157, 445-452 (1993)				
1	CS	Marguardt et al., J. Natl. Cancer Inst., 83, 1098-1102 (1991)				
CT CU CV CW CX CY		Martinez-Zaguilan et al., Am. J. Physiol., 265, C1015-C1029 (1993)				
		Martinez-Zaguilan et al., Ann. NY Acad. Sci., 671, 478-480 (1992)  Martinez-Zaguilan et al., Am. J. Physiol., 176, 196-205 (1998)				
		McKee et al., J. Org. Chem., 63, 7805-7810 (1998)				
		Mellman et al., Ann. Rev. Biochem., 55, 663-699 (1986)				
		Mohamadi et al., J. Computat. Chem., 11, 440-467 (1990)				
		Monks et al., J. Natl. Cancer Inst., 83, 757-766 (1991)				
		_	DB	Montcourrier et al., Clin. Exp. Metastatis, 15, 382-392 (1997)		
-	DC	Montcourrier et al., J. Cell Sci., 107, 2381-2391 (1994)				
_	DD	Moriyama et al., J. Biochem., 115, 213-218 (1994)				
	DE	Murray et al., Aust. J. Chem., 48, 1253-1266 (1995)				
	DF	Nelson, TIPS, 12, 71-75 (1991)				
1	DG	Nishihara et al., Biochem Biophys. Res. Commun., 212, 255-262 (1995)				
	DH	Oh et al., J. Org. Chem., 54, 4499-4503 (1989)				
-	DI	Ohkuma et al., In Vitro Cell Devel. Biol., 29A, 862-866 (1993)				
DJ		Ohta et al., J. Pathol., 185, 324-330 (1998)				
-	DK	Ohtani et al., J. Org. Chem., 56, 1296-1297 (1991)				
	DL	Parameswaran et al., Chemical Abstracts, 120, 600 (1994)				
	DM	Paull et al., Cancer Chemotherapeutic Agents (Foye, ed.), Washington, D.C.: American				
-		Chemical Society Books, 9-45, (1995)		_		
	DN	Paull et al., Cancer Res., 52, 3892-3900 (1992)				
	DO	Perona et al., Nature, 334, 438-440 (1988)		_		
	DP	Rashid et al., J. Nat. Prod., 58, 7, 1120-1125 (1995)		_		
	DQ	Rochfort et al., Aust. J. Chem., 49, 1217-1219 (1996)	<u> </u>	_		
	DR	Roesener et al., J. Am. Chem. Soc., 108, 846-847 (1986)		_		
$\neg$	DS	Rovinski et al., J. Natural Prod., 47, 3, 557 (1984)				
1/	DT	Rubinstein et al., J. Natl. Cancer Inst., 82,1113-1118 (1990)				
V	DŲ	Sausville, Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and	I			
•		Approval (Teicher, B.A., ed.) Totowa, NJ: Humana Press, Inc., pp. 217-226 (1997)		-		
/SW/	DV	Shimojima et al., J. Med. Chem., 26, 1370-1374 (1983)				

Examiner Signature	/Shengjun Wang/	Date Considered	04/24/2008	٦

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-largua equivalent/part, or an English-larguage abstract or an English-larguage version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in fleu of a concise explanation of relevance under 2 OFF1.188(a)(5).

Please type a plus sign (+) inside this box ->	Н

Substitute for form 1449A/B/PTO	
INFORMATION DISCLOSU	RE
STATEMENT BY APPLICAL	NT

(Use as many sheets as necessary)

Sheet 4 of 4

Complete if Known			
Application Number	09/914,708		
Filing Date	August 31, 2001		
First Named Inventor	BOYD, Michael R.		
Group Art Unit	1617		
Examiner Name	Shengjun Wang		
Attorney Docket Number	213045		
Client Reference No.	E-244-1997/3-US-06		

OTHER - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, Translatic					
Examiner Initials	Doc. No.	DOC.   magazine journel portal symposium catalog etc.) date page(e) volume-issue number (e) publisher city			
SW/	DW	Shimojima et al., J. Med. Chem., 28, 3-9 (1985)			
	DX	Shimojima et al., Tetrahedron Lett., 23, 51, 5435-5438 (1982)			
1	DY	Skehan et al., J. Natl. Cancer Inst., 82, 1107-1112 (1990)			
1	DZ	Stevens et al., Annu. Rev. Cell Dev. Bio., 13, 779-808 (1997)			
1	EΑ	Stinson et al., Anitcancer Res., 12, 1035-1054 (1992)			
1	EB	Stone et al., Kidney Int., 33, 767-774 (1988)			
1	EC	Suzumura et al., Tetrahedron Lett., 38, 43, 7573-7576 (1997)			
1	ED	Urry et al., Tetrahedron, 27, 3109-3114 (1966)			
1	EE	Vaananen et al, J. Cell, Biol., 111, 1305-1311 (1990)			
1	EF	Venkateswarlu et al., J. Natural Prod., 57, 9, 1283-1285 (1994)			
1	EG	Wang et al., J. Biol. Chem., 265, 21957-21965 (1990)			
1	EH	Ward et al., Tetrahedron, 51, 45, 12301-12318 (1995)			
1	EI	Wassaman, Science, 235, 553-560 (1987)			
1	EJ	Weinstein et al., Science, 275, 343-349 (1997)			
A	EK	Windholz et al., J. Org. Chem., 37, 10, 1647-1651 (1972)			
*	EL	Wolkowski et al., Tetrahedron Lett., 565-568 (1972)			
/SW/	EM	Zhi et al., 11 Plant Biochem., 123 ,123: 193621t (1995)			
1011					
	<del>                                     </del>				
			1		
			1		
	<b>—</b>		<del>                                     </del>	_	
	-				
	<b></b> -				
	<b></b> -		1		
			1	T	
	<del>                                     </del>			T	
			+	Т	
				1	
	-		+	$\vdash$	
	+		-	T	
			+-	+-	

Examiner Signature	/Shengjun Wang/	Date Considered	04/24/2008	

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-larguage equivalent/placer, or an English-larguage abstract, or an English-larguage version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in feu of a concise explanation of relevance under 3° CPRT, 196(a)(5).